Is Cerebrolysin FDA approved?

Cerebrolysin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Cerebrolysin administered in research settings?

In research settings, Cerebrolysin is typically administered via the intravenous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

How is Dihexa administered in research settings?

In research settings, Dihexa is typically administered via the oral, transdermal, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerebrolysin vs Dihexa

Peptide Comparison

Cerebrolysin vs Dihexa

Name: Cerebrolysin vs Dihexa — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Neuro & Cognitive peptides.

Cerebrolysin

FPF 1070

CognitiveInvestigationalResearch Only

Half-life: Varies by component

33 providers listed

Full Cerebrolysin profile →

Dihexa

PNB-0408

CognitiveResearch Only

Half-life: Unknown (likely days based on effects)

51 providers listed

Full Dihexa profile →

Bottom line

Cerebrolysin carries stronger published evidence (Meta-analysis, 5 key studies) than Dihexa (Review, 2); both are research compounds.

Quick Verdict

Cerebrolysin

Dihexa

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cerebrolysin
Further along in FDA review	Cerebrolysin
Oral administration option	Dihexa
More provider options (33 vs 51)	Dihexa

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerebrolysin

Dihexa

Mechanism Family

Neuro & Cognitive

Half-life

Varies by component

Unknown (likely days based on effects)

FDA Status

investigational

nomination withdrawn

Admin Routes

intravenous, intramuscular

oral, transdermal, subcutaneous

Availability

Research Only

Providers

33 listed

51 listed

Avail. Notes

Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.

Angiotensin IV-derived hexapeptide (PNB-0408) from WSU research. Cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Research compound only.

Research Evidence

Cerebrolysin

Meta-analysis · 5 key studies · most recent 2026

Dihexa

Review · 2 key studies · dated evidence base — most recent 2002

Research Citations

Cerebrolysin

Meta-analysis2019 · Cochrane Database of Systematic Reviews

Cerebrolysin for vascular dementia

Cohort2026 · Asian J Neurosurg

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Mon…

RCT2024 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a thre…

In vitro2026 · Cells

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothel…

+1 more

Dihexa

Animal2001 · Peptides

Angiotensin IV enhances LTP in rat dentate gyrus in vivo

Review2002 · Neuroscience and Biobehavioral Reviews

Neural plasticity and the brain renin-angiotensin system

About Cerebrolysin

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Research Areas

neuroprotectionneuroplasticitymemory improvementcognitive recovery

About Dihexa

HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models

Research Areas

HGF/MET receptor potentiation supporting synaptogenesishippocampal LTP enhancement in preclinical modelsmemory and neuroplasticity support (rodent data)no established human safety or pharmacokinetic profile

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerebrolysin

Reported (Unverified — Pending Clinical Review)

epilepsyrenal failureporcine protein allergy

No established clinical contraindications

Dihexa

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

Cerebrolysin

$0.83/mg

$0.82 – $0.83 range

9 vendors

View price index →Find providers →

Dihexa

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cerebrolysin

33 listed

Browse directory →

Providers offering

Dihexa

51 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cerebrolysin vs Dihexa — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cerebrolysin/dihexa

https://peptidebase.io/peptides/compare/cerebrolysin/dihexa Methodology License Download JSON Download CSV